A byproduct produced by certain gut bacteria may directly accelerate the brain changes associated with Alzheimer’s disease. Elevated blood levels of this molecule, known as imidazole propionate, correlate with worse cognitive decline in humans and actively drive neurodegeneration in animal models. The findings were published in Nature Communications.
The human digestive tract contains trillions of bacteria that help break down food. During this process, microbes release chemical byproducts into the bloodstream. These chemicals, called metabolites, travel throughout the body and influence the function of various organs, including the brain.
Imidazole propionate is a specific metabolite generated when gut bacteria break down histidine, an amino acid found in many common foods. Previous research linked elevated levels of this molecule to metabolic conditions like type 2 diabetes and heart disease. Because metabolic problems often increase the risk of developing dementia, researchers suspected the chemical might also affect brain health.
Researchers Vaibhav Vemuganti and Jea Woo Kang from the University of Wisconsin-Madison led the investigation alongside senior authors Barbara B. Bendlin and Federico E. Rey. They aimed to test whether imidazole propionate directly influences the biological pathways involved in cognitive aging and Alzheimer’s disease.
The team began by analyzing blood samples from nearly 1,200 older adults, most of whom had no diagnosed cognitive impairment. They measured the concentration of imidazole propionate in each participant’s blood and compared those levels against the participants’ scores on standardized memory and problem-solving tests. To isolate the effects of the chemical, the researchers adjusted their calculations for age, sex, body mass index, and the APOE gene, a known genetic risk factor for Alzheimer’s disease.
People with the highest levels of the gut metabolite performed worse on cognitive tests at the start of the study. Over years of follow-up visits, these same individuals experienced an earlier and more rapid decline in memory and executive function compared to those with lower levels. Statistical models predicted that the cognitive performance of the high-metabolite group fell below that of the low-metabolite group roughly 15 to 18 years before the participants’ average age.
To look for underlying physical changes, the researchers measured molecular markers of Alzheimer’s disease in the participants’ blood and cerebrospinal fluid. Cerebrospinal fluid is the clear liquid that surrounds and protects the brain and spinal cord. High blood levels of imidazole propionate correlated with elevated amounts of tau tangles and neurofilament light chain, a structural protein that leaks out of damaged brain cells.
The researchers then analyzed the genetic material of gut bacteria from fecal samples provided by 294 participants. They specifically searched for a bacterial gene called urdA, which provides the biological instructions for making the enzyme that produces imidazole propionate. They identified this gene in several bacterial families, including certain strains of Streptococcus.
A higher abundance of bacteria carrying this gene was linked to lower cognitive scores and elevated Alzheimer’s biomarkers in the human participants. To investigate if this relationship is a direct cause and effect in humans, the team turned to large genetic databases. They used a statistical method that treats genetic inheritance like a randomized trial to evaluate whether naturally occurring biological traits lead to specific diseases.
The analysis revealed a specific genetic variant on chromosome 12 that causes some people to naturally accumulate higher levels of imidazole propionate in their blood. Carrying this genetic variant was associated with an increased risk of developing Alzheimer’s disease, suggesting the metabolite actively promotes the condition rather than acting as a harmless bystander.
The researchers then conducted small studies using two different mouse models genetically engineered to develop Alzheimer’s-like brain changes. One model mimics the buildup of amyloid plaques, while the other mimics the accumulation of tau tangles. The researchers added imidazole propionate to the animals’ drinking water for several months.
In mice predisposed to accumulating amyloid plaques, a sticky protein fragment associated with Alzheimer’s, the treated animals developed more plaques in their brains than mice drinking regular water. In a second group of mice predisposed to tau tangles, the treatment caused severe inflammation and triggered the hyperactivity of star-shaped support cells called astrocytes. By analyzing the entire spectrum of proteins in the mouse brains, the researchers also detected elevated levels of proteins linked to structural breakdown in the nerve fibers.
Because the metabolite originates in the gut, it must travel through the blood to reach the brain. The researchers tested how the chemical affects the blood-brain barrier, a tightly packed layer of cells that lines brain blood vessels and protects neural tissue from circulating toxins.
They exposed human brain blood vessel cells to the metabolite in a laboratory setting. The molecule reduced the electrical resistance of the cell layer, indicating a breakdown in barrier integrity. In a separate test, the researchers injected a blue dye into the bloodstream of treated mice. The dye leaked extensively into the brain tissue, showing that the chemical damages blood vessels and allows substances to abnormally enter the brain.
In a final set of experiments, the team applied the metabolite directly to isolated mouse neurons grown in culture. They also added a chemical inhibitor that blocks an enzyme called GSK3-beta. This enzyme is known to abnormally attach phosphate molecules to tau proteins, causing them to tangle and destroy brain cells.
Exposure to the gut metabolite caused the cultured neurons to rapidly accumulate damaged tau proteins. Blocking the GSK3-beta enzyme completely reversed this effect, outlining the specific molecular pathway the gut chemical uses to damage brain cells.
While the human observational data points to a strong relationship, it cannot definitively prove that lowering imidazole propionate will prevent dementia. The animal experiments relied entirely on male mice given the chemical in their drinking water, which may not perfectly replicate how the metabolite is naturally produced and absorbed in the human digestive system.
Future studies will need to test female animals to determine if the biological effects differ by sex. Researchers will also need to explore whether specific dietary changes or targeted medications can safely reduce the production of this metabolite in the human gut.
The study, “Gut bacterial metabolite imidazole propionate potentiates Alzheimer’s disease pathology,” was authored by Vaibhav Vemuganti, Jea Woo Kang, Qijun Zhang, Eric R. McGregor, James R. Hilser, Ruben Aquino-Martinez, Sandra Harding, Joseph Lawrence Harpt, Katharina R. Beck, Hailey Bussan, Jessamine F. Kuehn, Yuetiva Deming, Rachel Studer, Sterling C. Johnson, Sanjay Asthana, Henrik Zetterberg, Kaj Blennow, Corinne D. Engelman, Hooman Allayee, Rozalyn M. Anderson, Tyler K. Ulland, Fredrik Bäckhed, Barbara B. Bendlin, and Federico E. Rey.